rickson personal page - To The Moon

rickson

rickson

No personal profile

192Follow

7Followers

0Topic

0Badge

03-31

T

@JC888:Tesla Downgraded: Is the Rally Over?

2022-02-04

a

3 Dividend Stocks That Can Make You Richer in February (and Beyond)

2022-02-04

a

Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance

2021-07-06

Good

3 Top Stocks That'll Make You Richer in the Second Half of 2021 (and Beyond)

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":4087654114933110,"uuid":"4087654114933110","gmtCreate":1624594075086,"gmtModify":1668100482178,"name":"rickson","pinyin":"rickson","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":192,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":290200896983200,"gmtCreate":1711856467479,"gmtModify":1711856470727,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","crmLevel":1,"crmLevelSwitch":1},"themes":[],"htmlText":"T","listText":"T","text":"T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/290200896983200","repostId":"289834473468104","repostType":1,"repost":{"id":289834473468104,"gmtCreate":1711766915373,"gmtModify":1711844401900,"author":{"id":"3570103090255456","authorId":"3570103090255456","name":"JC888","avatar":"https://community-static.tradeup.com/news/f3e3c0218599fca5c4e265ddbee1fb32","crmLevel":4,"crmLevelSwitch":1},"themes":[],"title":"Tesla Downgraded: Is the Rally Over? ","htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"0\"></v-v> Does the above picture remind you of 1991 US movie “Thelma and Louise” ‘s last scene where the two women decided to drive off a cliff instead of being apprehended by the cops? It is definitely “death by choice”. The above picture also resembles the “deep shit” status Tesla is encountering now. Bad news - one after another! In March 2024 alone, four notable funds houses&nbsp;downgraded Tesla: (1) Citibank, Analyst, Itay Michaeli: On Wed, 27 Mar 2024, analyst lowered price target from $224 to $196. Rating: Neutral. Q1 Delivery: Revised down from 473,300 to 429,9000 EVs. This is a massive, short of 43,400 EVs. Will leave it to the fans to translate that into top line, bottom line and margin. Micha","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"0\"></v-v> Does the above picture remind you of 1991 US movie “Thelma and Louise” ‘s last scene where the two women decided to drive off a cliff instead of being apprehended by the cops? It is definitely “death by choice”. The above picture also resembles the “deep shit” status Tesla is encountering now. Bad news - one after another! In March 2024 alone, four notable funds houses&nbsp;downgraded Tesla: (1) Citibank, Analyst, Itay Michaeli: On Wed, 27 Mar 2024, analyst lowered price target from $224 to $196. Rating: Neutral. Q1 Delivery: Revised down from 473,300 to 429,9000 EVs. This is a massive, short of 43,400 EVs. Will leave it to the fans to translate that into top line, bottom line and margin. Micha","text":"$Tesla Motors(TSLA)$ Does the above picture remind you of 1991 US movie “Thelma and Louise” ‘s last scene where the two women decided to drive off a cliff instead of being apprehended by the cops? It is definitely “death by choice”. The above picture also resembles the “deep shit” status Tesla is encountering now. Bad news - one after another! In March 2024 alone, four notable funds houses downgraded Tesla: (1) Citibank, Analyst, Itay Michaeli: On Wed, 27 Mar 2024, analyst lowered price target from $224 to $196. Rating: Neutral. Q1 Delivery: Revised down from 473,300 to 429,9000 EVs. This is a massive, short of 43,400 EVs. Will leave it to the fans to translate that into top line, bottom line and margin. Micha","images":[{"img":"https://community-static.tradeup.com/news/9b35336cfc779802348d66dc13a4d858","width":"1379","height":"468"},{"img":"https://community-static.tradeup.com/news/90fc2631db3946611217348c11f1726f","width":"1046","height":"643"},{"img":"https://community-static.tradeup.com/news/a451a0b1155e54f3ff225fbd062579c0","width":"672","height":"162"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/289834473468104","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098036848,"gmtCreate":1643965151941,"gmtModify":1676533876775,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","crmLevel":1,"crmLevelSwitch":1},"themes":[],"htmlText":"a","listText":"a","text":"a","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098036848","repostId":"2208395864","repostType":4,"repost":{"id":"2208395864","pubTimestamp":1643961961,"share":"https://www.laohu8.com/m/news/2208395864?lang=&edition=full","pubTime":"2022-02-04 16:06","market":"us","language":"en","title":"3 Dividend Stocks That Can Make You Richer in February (and Beyond)","url":"https://stock-news.laohu8.com/highlight/detail?id=2208395864","media":"Motley Fool","summary":"These income stocks are screaming bargains following the recent market sell-off.","content":"<html><head></head><body><p>You may not like what I&#39;m about to say, but stock market crashes and corrections are an inevitable and normal part of the investing cycle.</p><p>Last month, the widely followed <b>S&amp;P 500</b> and tech-heavy <b>Nasdaq Composite</b> endured their steepest corrections since the March 2020 pandemic-induced crash.</p><p>However, every crash, correction, and sizable pullback throughout history has represented an opportunity for patient investors to put their money to work in the stock market at a discount. It could be an especially perfect time to put your money to work in dividend stocks.</p><p>The answer to &#34;Why dividend stocks?&#34; is simple: They&#39;re moneymakers. Dividend stocks are almost always profitable, have time-tested operating models, and offer a rich history of outperformance, relative to non-dividend-paying stocks.</p><p>Back in 2013, J.P. Morgan Asset Management, a division of banking giant <b>JPMorgan Chase</b>, released a report comparing the performance of companies that initiated and grew their dividend to non-payers over a four-decade stretch (1972-2012). The results showed a 9.5% annualized gain over 40 years for the dividend stocks versus a meager 1.6% annualized gain for those that didn&#39;t pay a dividend.</p><p>Following the market&#39;s significant pullback, three dividend stocks stand out as having all the tools needed to make you richer in February, and well beyond.</p><h2>Bank of America</h2><p>The first dividend stock begging to be bought by income seekers in February is money-center giant <b>Bank of America</b> (NYSE:BAC).</p><p>Bank stocks are inherently cyclical. This means they struggle when the U.S. and/or global economy are in recession and thrive when the opposite is true. What&#39;s important to understand is that there&#39;s a large timeline disparity between economic expansions and recessions. Whereas contractions and recessions are often measured in months or quarters, periods of expansion last for years. Buying bank stocks like BofA often allows patient investors to take advantage of growing economies over time.</p><p>But there&#39;s another exciting reason why Bank of America stands out. Among money-center banks, none is more interest-sensitive than BofA. This distinction is important given that U.S. inflation is at a 40-year high, and the Federal Reserve appears ready to hike interest rates on multiple occasions in 2022 and 2023. According to Bank of America&#39;s fourth-quarter operating results, a 100-basis-point parallel shift in the interest rate yield curve would result in an estimated $6.5 billion in added net interest income over 12 months. In short, we&#39;re about to see extra interest income from outstanding variable-rate loans flow directly to BofA&#39;s bottom line and boost its earnings per share.</p><p>Investors should take notice of Bank of America&#39;s digitization efforts as well. Over the previous three years, the company&#39;s digital active user count has grown 5 million to 41 million, with the percentage of sales completed online or via mobile app surging to 49% from 31%. Because digital sales are considerably cheaper for the company than in-person and phone-based interactions, this digital shift has allowed BofA to consolidate some of its branches and reduce its expenses.</p><p>Though Bank of America&#39;s 1.8% yield isn&#39;t eye-popping, keep in mind that it offers <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most generous shareholder return policies among big banks. With higher profits likely around the corner, look for BofA to boost its dividend and share repurchase program by midyear.</p><h2>Kinross Gold</h2><p>A second dividend stock that can make investors richer in February and well beyond is gold miner <b>Kinross Gold</b> (NYSE:KGC).</p><p>It probably goes without saying, but investors can&#39;t be bullish on gold stocks without having a positive outlook for the lustrous yellow metal. The good news is that gold does offer a favorable outlook. Historically low lending rates coupled with high inflation have made it very difficult for income investors to generate real-money returns. With gold serving as a hedge to inflation and fear, it should perform well throughout 2022.</p><p>On a more company-specific basis, Kinross Gold is set to benefit from production upgrades at a key mine. While the Tasiast mine in Mauritania has, at times, been more trouble than it&#39;s worth, this key asset could nearly double its gold output over the next two years. By the end of the first quarter, the Tasiast 21k project, which&#39;ll increase mine throughput to 21,000 tonnes per day, will be complete. By mid-2023, throughput will hit 24,000 tonnes per daily. Once the full ramp-up is complete, Tasiast will be a flagship asset with all-in sustaining costs of around $560 per gold ounce. This equates to a cash operating margin of more than $1,200/ounce, based on where physical gold stands today ($1,800/oz.).</p><p>Furthermore, Kinross Gold has a veritable mountain of projects in development. Later this year, production will begin at the La Coipa mine, with first production anticipated from Manh Choh and Udinsk in 2024 and late 2025, respectively. Between organic mine expansion and new assets coming online, Kinross expects gold equivalent ounce (GEO) production to rocket from 2.1 million in 2021 to 2.9 million GEO in 2023.</p><p>In addition to a healthy pipeline, Kinross Gold&#39;s assets offer reasonably long lifespans. Taking into account expected reserve and resource life, the majority of Kinross&#39; core mines are expected to be producing for 15 or more years.</p><p>Currently sporting a market-topping 2.3% yield, Kinross Gold can be scooped up for less than seven times Wall Street&#39;s consensus earnings forecast for 2022. It has an even lower multiple if taking into account the company&#39;s operating cash flow. It&#39;s simply too great a deal for income investors to pass up.</p><h2>Merck</h2><p>A third dividend stock investors can confidently buy to become richer in February, and likely well beyond, is pharmaceutical stock <b>Merck</b> (NYSE:MRK).</p><p>The beauty of healthcare stocks like Merck is they&#39;re highly defensive. Even though they may decline in sympathy with the broader market during pullbacks, their operating performance remains largely unaffected by economic contractions and stock market moves. Since we don&#39;t get to control when we get sick or what ailment(s) we develop, there tends to be steady demand for prescription drugs, medical devices, and healthcare services.</p><p>The key driver for Merck&#39;s bottom line continues to be cancer immunotherapy Keytruda, which has more approved indications in the U.S. than I can count. During the third quarter, Keytruda brought in $4.53 billion in sales, which equates to more than $18 billion in annual run-rate revenue. Between multiple ongoing clinical trials that could expand its label and strong pricing power, Keytruda could well become the world&#39;s top-selling drug in the years to come (not counting COVID-19 vaccines).</p><p>Merck also hasn&#39;t been afraid to lean on inorganic opportunities to lift its growth rate and diversify its sales channels away from Keytruda. Last year, it spent $11.5 billion to acquire Acceleron Pharma to gain hold of sotatercept. This late-stage clinical therapy has shown promise as an add-on treatment to the current standard of care in patients with pulmonary arterial hypertension. While estimates vary, the expectation is for sotatercept to top $1 billion in peak annual sales, if approved.</p><p>However, Merck is about more than just brand-name pharmaceuticals. The company&#39;s animal health division is making waves with consistent double-digit growth. In particular, companion animal therapeutics have been especially strong. With more U.S. households than ever owning a pet, Merck&#39;s animal health segment can shine.</p><p>Investors can gobble up this pharma giant for a reasonably low 11 times Wall Street&#39;s forecast earnings in 2022, and they&#39;ll be rewarded with a hearty 3.4% dividend yield for their patience.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks That Can Make You Richer in February (and Beyond)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks That Can Make You Richer in February (and Beyond)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 16:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/03/3-dividend-stocks-can-make-you-richer-in-february/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may not like what I'm about to say, but stock market crashes and corrections are an inevitable and normal part of the investing cycle.Last month, the widely followed S&P 500 and tech-heavy Nasdaq ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/03/3-dividend-stocks-can-make-you-richer-in-february/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","GEO":"GEO惩教集团","BK4084":"特种房地产投资信托","BK4553":"喜马拉雅资本持仓","BK4207":"综合性银行","BK4017":"黄金","BK4547":"WSB热门概念","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BAC":"美国银行","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4504":"桥水持仓","KGC":"金罗斯黄金","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4516":"特朗普概念"},"source_url":"https://www.fool.com/investing/2022/02/03/3-dividend-stocks-can-make-you-richer-in-february/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208395864","content_text":"You may not like what I'm about to say, but stock market crashes and corrections are an inevitable and normal part of the investing cycle.Last month, the widely followed S&P 500 and tech-heavy Nasdaq Composite endured their steepest corrections since the March 2020 pandemic-induced crash.However, every crash, correction, and sizable pullback throughout history has represented an opportunity for patient investors to put their money to work in the stock market at a discount. It could be an especially perfect time to put your money to work in dividend stocks.The answer to \"Why dividend stocks?\" is simple: They're moneymakers. Dividend stocks are almost always profitable, have time-tested operating models, and offer a rich history of outperformance, relative to non-dividend-paying stocks.Back in 2013, J.P. Morgan Asset Management, a division of banking giant JPMorgan Chase, released a report comparing the performance of companies that initiated and grew their dividend to non-payers over a four-decade stretch (1972-2012). The results showed a 9.5% annualized gain over 40 years for the dividend stocks versus a meager 1.6% annualized gain for those that didn't pay a dividend.Following the market's significant pullback, three dividend stocks stand out as having all the tools needed to make you richer in February, and well beyond.Bank of AmericaThe first dividend stock begging to be bought by income seekers in February is money-center giant Bank of America (NYSE:BAC).Bank stocks are inherently cyclical. This means they struggle when the U.S. and/or global economy are in recession and thrive when the opposite is true. What's important to understand is that there's a large timeline disparity between economic expansions and recessions. Whereas contractions and recessions are often measured in months or quarters, periods of expansion last for years. Buying bank stocks like BofA often allows patient investors to take advantage of growing economies over time.But there's another exciting reason why Bank of America stands out. Among money-center banks, none is more interest-sensitive than BofA. This distinction is important given that U.S. inflation is at a 40-year high, and the Federal Reserve appears ready to hike interest rates on multiple occasions in 2022 and 2023. According to Bank of America's fourth-quarter operating results, a 100-basis-point parallel shift in the interest rate yield curve would result in an estimated $6.5 billion in added net interest income over 12 months. In short, we're about to see extra interest income from outstanding variable-rate loans flow directly to BofA's bottom line and boost its earnings per share.Investors should take notice of Bank of America's digitization efforts as well. Over the previous three years, the company's digital active user count has grown 5 million to 41 million, with the percentage of sales completed online or via mobile app surging to 49% from 31%. Because digital sales are considerably cheaper for the company than in-person and phone-based interactions, this digital shift has allowed BofA to consolidate some of its branches and reduce its expenses.Though Bank of America's 1.8% yield isn't eye-popping, keep in mind that it offers one of the most generous shareholder return policies among big banks. With higher profits likely around the corner, look for BofA to boost its dividend and share repurchase program by midyear.Kinross GoldA second dividend stock that can make investors richer in February and well beyond is gold miner Kinross Gold (NYSE:KGC).It probably goes without saying, but investors can't be bullish on gold stocks without having a positive outlook for the lustrous yellow metal. The good news is that gold does offer a favorable outlook. Historically low lending rates coupled with high inflation have made it very difficult for income investors to generate real-money returns. With gold serving as a hedge to inflation and fear, it should perform well throughout 2022.On a more company-specific basis, Kinross Gold is set to benefit from production upgrades at a key mine. While the Tasiast mine in Mauritania has, at times, been more trouble than it's worth, this key asset could nearly double its gold output over the next two years. By the end of the first quarter, the Tasiast 21k project, which'll increase mine throughput to 21,000 tonnes per day, will be complete. By mid-2023, throughput will hit 24,000 tonnes per daily. Once the full ramp-up is complete, Tasiast will be a flagship asset with all-in sustaining costs of around $560 per gold ounce. This equates to a cash operating margin of more than $1,200/ounce, based on where physical gold stands today ($1,800/oz.).Furthermore, Kinross Gold has a veritable mountain of projects in development. Later this year, production will begin at the La Coipa mine, with first production anticipated from Manh Choh and Udinsk in 2024 and late 2025, respectively. Between organic mine expansion and new assets coming online, Kinross expects gold equivalent ounce (GEO) production to rocket from 2.1 million in 2021 to 2.9 million GEO in 2023.In addition to a healthy pipeline, Kinross Gold's assets offer reasonably long lifespans. Taking into account expected reserve and resource life, the majority of Kinross' core mines are expected to be producing for 15 or more years.Currently sporting a market-topping 2.3% yield, Kinross Gold can be scooped up for less than seven times Wall Street's consensus earnings forecast for 2022. It has an even lower multiple if taking into account the company's operating cash flow. It's simply too great a deal for income investors to pass up.MerckA third dividend stock investors can confidently buy to become richer in February, and likely well beyond, is pharmaceutical stock Merck (NYSE:MRK).The beauty of healthcare stocks like Merck is they're highly defensive. Even though they may decline in sympathy with the broader market during pullbacks, their operating performance remains largely unaffected by economic contractions and stock market moves. Since we don't get to control when we get sick or what ailment(s) we develop, there tends to be steady demand for prescription drugs, medical devices, and healthcare services.The key driver for Merck's bottom line continues to be cancer immunotherapy Keytruda, which has more approved indications in the U.S. than I can count. During the third quarter, Keytruda brought in $4.53 billion in sales, which equates to more than $18 billion in annual run-rate revenue. Between multiple ongoing clinical trials that could expand its label and strong pricing power, Keytruda could well become the world's top-selling drug in the years to come (not counting COVID-19 vaccines).Merck also hasn't been afraid to lean on inorganic opportunities to lift its growth rate and diversify its sales channels away from Keytruda. Last year, it spent $11.5 billion to acquire Acceleron Pharma to gain hold of sotatercept. This late-stage clinical therapy has shown promise as an add-on treatment to the current standard of care in patients with pulmonary arterial hypertension. While estimates vary, the expectation is for sotatercept to top $1 billion in peak annual sales, if approved.However, Merck is about more than just brand-name pharmaceuticals. The company's animal health division is making waves with consistent double-digit growth. In particular, companion animal therapeutics have been especially strong. With more U.S. households than ever owning a pet, Merck's animal health segment can shine.Investors can gobble up this pharma giant for a reasonably low 11 times Wall Street's forecast earnings in 2022, and they'll be rewarded with a hearty 3.4% dividend yield for their patience.","news_type":1},"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098036986,"gmtCreate":1643965069659,"gmtModify":1676533876728,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","crmLevel":1,"crmLevelSwitch":1},"themes":[],"htmlText":"a","listText":"a","text":"a","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098036986","repostId":"1162337054","repostType":4,"repost":{"id":"1162337054","pubTimestamp":1643964793,"share":"https://www.laohu8.com/m/news/1162337054?lang=&edition=full","pubTime":"2022-02-04 16:53","market":"us","language":"en","title":"Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162337054","media":"Seeking Alpha","summary":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by","content":"<html><head></head><body><ul><li>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.</li><li>Revenue of €9.99B misses by €120M(+6.5% Y/Y).</li><li>Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.</li><li>Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.</li><li>General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestitures</li><li>CHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.</li><li><b>2022 financial outlook</b>: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Non-GAAP EPS of €1.38 Beats by €0.02, Revenue of €9.99B Misses by €120M; Initiates FY22 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +...</p>\n\n<a href=\"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3795918-sanofi-non-gaap-eps-of-138-beats-by-002-revenue-of-999b-misses-by-120m-initiates-fy22-guidance","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162337054","content_text":"Sanofipress release(NASDAQ:SNY): Q4 Non-GAAP EPS of €1.38 beats by €0.02.Revenue of €9.99B misses by €120M(+6.5% Y/Y).Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent®+53.1%.Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3.General Medicines core assets up 2.1%, while GBU sales decreased -3.8% mainly due to prioritization and divestituresCHC continued growth momentum +5.6%, driven by Cough and Cold, Pain care and Digestive Wellness categories.2022 financial outlook: Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average January 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +2% to +3% vs. estimated growth of 12.55% Y/Y.","news_type":1},"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157925279,"gmtCreate":1625560884091,"gmtModify":1703743754575,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","crmLevel":1,"crmLevelSwitch":1},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157925279","repostId":"2149033827","repostType":4,"repost":{"id":"2149033827","pubTimestamp":1625542083,"share":"https://www.laohu8.com/m/news/2149033827?lang=&edition=full","pubTime":"2021-07-06 11:28","market":"us","language":"en","title":"3 Top Stocks That'll Make You Richer in the Second Half of 2021 (and Beyond)","url":"https://stock-news.laohu8.com/highlight/detail?id=2149033827","media":"Motley Fool","summary":"This mix of growth and value stocks can make investors a boatload of money.","content":"<p>If there's one lesson the stock market is always willing to teach, it's that patience pays off. Despite navigating its way through the Black Monday crash in 1987, the dot-com bubble, the Great Recession, and the coronavirus crash, the benchmark <b>S&amp;P 500</b> has delivered an average annual total return of more than 11% since the beginning of 1980.</p>\n<p>Patience can pay off for you, as well, if you put your money to work in game-changing businesses and allow your investment thesis to play out over time. As we move into the second-half of 2021, the following trio of top stocks has the potential to make you a lot richer.<img src=\"https://static.tigerbbs.com/eb8db31ebee93b248d65ac685c65dbac\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>If growth stocks tickle your fancy, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the best investments you can make right now for the second half of 2021, and well beyond, is cloud-based customer relationship management (CRM) software provider <b>salesforce.com</b> (NYSE:CRM).</p>\n<p>CRM software is used by consumer-facing businesses to optimize interactions and sales. It helps with real-time information logging, overseeing service and product issues, managing online marketing campaigns, and can offer predictive analysis of what existing clients might buy a new product or service. It's a sustainable double-digit growth opportunity that's been a no-brainer tool used by service-oriented industries, but is becoming more widely used by healthcare, financial, and industrial companies.</p>\n<p>Salesforce is the king of the mountain when it comes to cloud-based CRM. According to estimates from IDC, salesforce nearly controlled 20% of global CRM revenue share in the first-half of 2020. That nearly quadruples its next-closest competitor, and it <i>is</i> more than the four closest competitors, combined.</p>\n<p>In addition to growing its business organically, salesforce has a rich history of making smart acquisitions. Some of its most successful include purchasing Tableau Software in 2019, and MuleSoft in 2018. The latter is responsible for powering the Salesforce Integration Cloud, while the former is a data treasure trove that helps businesses gain a deeper understanding of their customers.</p>\n<p>The newest deal, tallying $27.7 billion, is for cloud-based enterprise communications platform <b><a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a></b>. This deal will allow the company to cross-sell its suite of CRM support solutions to Slack's bevy of small-and-medium-sized businesses.</p>\n<p>This combination of market share dominance, organic growth, and acquisitions has salesforce growing at 20% or more annually. Per CEO Marc Benioff, salesforce is on track to hit a goal of $50 billion in annual sales by fiscal 2026 (up from $21.3 billion in fiscal 2021). This is growth and dominance investors can trust.</p>\n<p><img src=\"https://static.tigerbbs.com/37d129c37c1dfcde03e04fddc2f9a834\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>SSR Mining</h2>\n<p>Don't worry, value investors, I haven't forgotten about you. A second top stock that can make you a lot richer in the latter half of 2021 (and beyond) is precious-metal miner <b>SSR Mining</b> (NASDAQ:SSRM).</p>\n<p>Roughly 10 years ago, gold and silver were soaring and precious-metal miners were liberally spending on new projects, existing mine expansions, and acquisitions. After the price of gold peaked, many were left with less-than-stellar balance sheets. That's not been the case with SSR Mining.</p>\n<p>Last year, SSR completed a merger of equals with Turkey's Alacer Gold. This effectively combined SSR's Marigold and Seabee gold mines, and its silver-producing Puna operations in Argentina, with Alacer's Copler gold mine. Altogether, these four producing assets should yield between 700,000 gold equivalent ounces (GEO) and 800,000 GEO annually for the next five years, if not longer. Prior to the deal, SSR was producing a little north of 400,000 GEO annually.</p>\n<p>Here's the thing: Whereas most gold stocks have scrambled to pay down debt, SSR is sitting on a net cash balance of around $400 million, as of the end of March 2021. The roughly $450 million the company is expecting to generate in annual free cash flow has allowed it to begin paying a $0.05 quarterly dividend, as well as institute a $150 million share buyback program.</p>\n<p>In addition to improved output, a dividend, and a share buyback program, SSR Mining should benefit from stronger precious-metal prices. The Federal Reserve continues to hold off on raising historically low lending rates, while the prospect for longer-term inflation is climbing. Both scenarios point to investors continuing to flock to gold as a potential store of value.</p>\n<p>Just how cheap is SSR Mining? Shares can currently be purchased for less than 9 times Wall Street's forward-year earnings estimate. Even more telling, SSR is valued at a multiple of 5 times this year's estimated cash flow, which implies a significant discount to a fair valuation, which I'd peg as closer to 10 times cash flow.</p>\n<p><img src=\"https://static.tigerbbs.com/de67cc325c8403c33a12cc0935dcf46f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>Trulieve Cannabis</h2>\n<p>A third company that can make investors richer in the second half of 2021 is marijuana stock <b>Trulieve Cannabis</b> (OTC:TCNNF).</p>\n<p>There's no question that cannabis is a sustainable double-digit growth opportunity. But considering the regulatory issues and atrocious balance sheets that accompany most Canadian pot stocks, the U.S. is the smart way to play the cannabis craze. By mid-decade, the U.S. could be bringing in more than $41 billion in annual weed sales, per <a href=\"https://laohu8.com/S/NFC.U\">New Frontier</a> Data.</p>\n<p>What makes multistate operator (MSO) Trulieve so special is how the company has chosen to expand. Many large MSOs have opened retail, cultivation, and processing facilities in as many legalized states as reasonable. As for Trulieve, it has 91 operational retail locations in the U.S., 85 of which are located in medical marijuana-legal Florida. That's right -- it's opened 85 dispensaries in a single state.</p>\n<p>How's that worked out? By blanketing the Sunshine State, Trulieve Cannabis has been able to gobble up 53% of Florida's dried cannabis market share and 49% of its higher-margin cannabinoid oils share. In other words, the company has effectively built up its brand and a loyal customer following without having to break the bank with its marketing budget. As a result, it recently reported its 13th consecutive profitable quarter.</p>\n<p>In May, we learned that the next chapter for Trulieve will entail taking its blueprint to new markets. On May 10, it announced a $2.1 billion deal to acquire MSO <b>Harvest Health &amp; Recreation</b> (OTC:HRVSF). Harvest Health has a five-state focus, one of which includes Florida. Thus, Trulieve will soon have an even larger presence in the Sunshine State. But the big driver of this deal is Harvest's 15 operational dispensaries in Arizona, which legalized adult-use cannabis in November and began sales in January. Nothing would stop Trulieve from becoming a dominant force in Arizona's potential billion-dollar weed market.</p>\n<p>With its rich history of profitability and stunning growth potential, Trulieve Cannabis checks all the right boxes to be a moneymaker for investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Stocks That'll Make You Richer in the Second Half of 2021 (and Beyond)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Stocks That'll Make You Richer in the Second Half of 2021 (and Beyond)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 11:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/05/3-top-stocks-make-you-richer-second-half-of-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If there's one lesson the stock market is always willing to teach, it's that patience pays off. Despite navigating its way through the Black Monday crash in 1987, the dot-com bubble, the Great ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/05/3-top-stocks-make-you-richer-second-half-of-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TCNNF":"Trulieve Cannabis Corporation","CRM":"赛富时","SSRM":"SSR Mining Inc"},"source_url":"https://www.fool.com/investing/2021/07/05/3-top-stocks-make-you-richer-second-half-of-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149033827","content_text":"If there's one lesson the stock market is always willing to teach, it's that patience pays off. Despite navigating its way through the Black Monday crash in 1987, the dot-com bubble, the Great Recession, and the coronavirus crash, the benchmark S&P 500 has delivered an average annual total return of more than 11% since the beginning of 1980.\nPatience can pay off for you, as well, if you put your money to work in game-changing businesses and allow your investment thesis to play out over time. As we move into the second-half of 2021, the following trio of top stocks has the potential to make you a lot richer.\nImage source: Getty Images.\nSalesforce\nIf growth stocks tickle your fancy, one of the best investments you can make right now for the second half of 2021, and well beyond, is cloud-based customer relationship management (CRM) software provider salesforce.com (NYSE:CRM).\nCRM software is used by consumer-facing businesses to optimize interactions and sales. It helps with real-time information logging, overseeing service and product issues, managing online marketing campaigns, and can offer predictive analysis of what existing clients might buy a new product or service. It's a sustainable double-digit growth opportunity that's been a no-brainer tool used by service-oriented industries, but is becoming more widely used by healthcare, financial, and industrial companies.\nSalesforce is the king of the mountain when it comes to cloud-based CRM. According to estimates from IDC, salesforce nearly controlled 20% of global CRM revenue share in the first-half of 2020. That nearly quadruples its next-closest competitor, and it is more than the four closest competitors, combined.\nIn addition to growing its business organically, salesforce has a rich history of making smart acquisitions. Some of its most successful include purchasing Tableau Software in 2019, and MuleSoft in 2018. The latter is responsible for powering the Salesforce Integration Cloud, while the former is a data treasure trove that helps businesses gain a deeper understanding of their customers.\nThe newest deal, tallying $27.7 billion, is for cloud-based enterprise communications platform Slack Technologies. This deal will allow the company to cross-sell its suite of CRM support solutions to Slack's bevy of small-and-medium-sized businesses.\nThis combination of market share dominance, organic growth, and acquisitions has salesforce growing at 20% or more annually. Per CEO Marc Benioff, salesforce is on track to hit a goal of $50 billion in annual sales by fiscal 2026 (up from $21.3 billion in fiscal 2021). This is growth and dominance investors can trust.\n\nImage source: Getty Images.\nSSR Mining\nDon't worry, value investors, I haven't forgotten about you. A second top stock that can make you a lot richer in the latter half of 2021 (and beyond) is precious-metal miner SSR Mining (NASDAQ:SSRM).\nRoughly 10 years ago, gold and silver were soaring and precious-metal miners were liberally spending on new projects, existing mine expansions, and acquisitions. After the price of gold peaked, many were left with less-than-stellar balance sheets. That's not been the case with SSR Mining.\nLast year, SSR completed a merger of equals with Turkey's Alacer Gold. This effectively combined SSR's Marigold and Seabee gold mines, and its silver-producing Puna operations in Argentina, with Alacer's Copler gold mine. Altogether, these four producing assets should yield between 700,000 gold equivalent ounces (GEO) and 800,000 GEO annually for the next five years, if not longer. Prior to the deal, SSR was producing a little north of 400,000 GEO annually.\nHere's the thing: Whereas most gold stocks have scrambled to pay down debt, SSR is sitting on a net cash balance of around $400 million, as of the end of March 2021. The roughly $450 million the company is expecting to generate in annual free cash flow has allowed it to begin paying a $0.05 quarterly dividend, as well as institute a $150 million share buyback program.\nIn addition to improved output, a dividend, and a share buyback program, SSR Mining should benefit from stronger precious-metal prices. The Federal Reserve continues to hold off on raising historically low lending rates, while the prospect for longer-term inflation is climbing. Both scenarios point to investors continuing to flock to gold as a potential store of value.\nJust how cheap is SSR Mining? Shares can currently be purchased for less than 9 times Wall Street's forward-year earnings estimate. Even more telling, SSR is valued at a multiple of 5 times this year's estimated cash flow, which implies a significant discount to a fair valuation, which I'd peg as closer to 10 times cash flow.\n\nImage source: Getty Images.\nTrulieve Cannabis\nA third company that can make investors richer in the second half of 2021 is marijuana stock Trulieve Cannabis (OTC:TCNNF).\nThere's no question that cannabis is a sustainable double-digit growth opportunity. But considering the regulatory issues and atrocious balance sheets that accompany most Canadian pot stocks, the U.S. is the smart way to play the cannabis craze. By mid-decade, the U.S. could be bringing in more than $41 billion in annual weed sales, per New Frontier Data.\nWhat makes multistate operator (MSO) Trulieve so special is how the company has chosen to expand. Many large MSOs have opened retail, cultivation, and processing facilities in as many legalized states as reasonable. As for Trulieve, it has 91 operational retail locations in the U.S., 85 of which are located in medical marijuana-legal Florida. That's right -- it's opened 85 dispensaries in a single state.\nHow's that worked out? By blanketing the Sunshine State, Trulieve Cannabis has been able to gobble up 53% of Florida's dried cannabis market share and 49% of its higher-margin cannabinoid oils share. In other words, the company has effectively built up its brand and a loyal customer following without having to break the bank with its marketing budget. As a result, it recently reported its 13th consecutive profitable quarter.\nIn May, we learned that the next chapter for Trulieve will entail taking its blueprint to new markets. On May 10, it announced a $2.1 billion deal to acquire MSO Harvest Health & Recreation (OTC:HRVSF). Harvest Health has a five-state focus, one of which includes Florida. Thus, Trulieve will soon have an even larger presence in the Sunshine State. But the big driver of this deal is Harvest's 15 operational dispensaries in Arizona, which legalized adult-use cannabis in November and began sales in January. Nothing would stop Trulieve from becoming a dominant force in Arizona's potential billion-dollar weed market.\nWith its rich history of profitability and stunning growth potential, Trulieve Cannabis checks all the right boxes to be a moneymaker for investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9098036986,"gmtCreate":1643965069659,"gmtModify":1676533876728,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","crmLevel":1,"crmLevelSwitch":1},"themes":[],"htmlText":"a","listText":"a","text":"a","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098036986","repostId":"1162337054","repostType":4,"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098036848,"gmtCreate":1643965151941,"gmtModify":1676533876775,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","crmLevel":1,"crmLevelSwitch":1},"themes":[],"htmlText":"a","listText":"a","text":"a","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098036848","repostId":"2208395864","repostType":4,"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":290200896983200,"gmtCreate":1711856467479,"gmtModify":1711856470727,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","crmLevel":1,"crmLevelSwitch":1},"themes":[],"htmlText":"T","listText":"T","text":"T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/290200896983200","repostId":"289834473468104","repostType":1,"repost":{"id":289834473468104,"gmtCreate":1711766915373,"gmtModify":1711844401900,"author":{"id":"3570103090255456","authorId":"3570103090255456","name":"JC888","avatar":"https://community-static.tradeup.com/news/f3e3c0218599fca5c4e265ddbee1fb32","crmLevel":4,"crmLevelSwitch":1},"themes":[],"title":"Tesla Downgraded: Is the Rally Over? ","htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"0\"></v-v> Does the above picture remind you of 1991 US movie “Thelma and Louise” ‘s last scene where the two women decided to drive off a cliff instead of being apprehended by the cops? It is definitely “death by choice”. The above picture also resembles the “deep shit” status Tesla is encountering now. Bad news - one after another! In March 2024 alone, four notable funds houses&nbsp;downgraded Tesla: (1) Citibank, Analyst, Itay Michaeli: On Wed, 27 Mar 2024, analyst lowered price target from $224 to $196. Rating: Neutral. Q1 Delivery: Revised down from 473,300 to 429,9000 EVs. This is a massive, short of 43,400 EVs. Will leave it to the fans to translate that into top line, bottom line and margin. Micha","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"0\"></v-v> Does the above picture remind you of 1991 US movie “Thelma and Louise” ‘s last scene where the two women decided to drive off a cliff instead of being apprehended by the cops? It is definitely “death by choice”. The above picture also resembles the “deep shit” status Tesla is encountering now. Bad news - one after another! In March 2024 alone, four notable funds houses&nbsp;downgraded Tesla: (1) Citibank, Analyst, Itay Michaeli: On Wed, 27 Mar 2024, analyst lowered price target from $224 to $196. Rating: Neutral. Q1 Delivery: Revised down from 473,300 to 429,9000 EVs. This is a massive, short of 43,400 EVs. Will leave it to the fans to translate that into top line, bottom line and margin. Micha","text":"$Tesla Motors(TSLA)$ Does the above picture remind you of 1991 US movie “Thelma and Louise” ‘s last scene where the two women decided to drive off a cliff instead of being apprehended by the cops? It is definitely “death by choice”. The above picture also resembles the “deep shit” status Tesla is encountering now. Bad news - one after another! In March 2024 alone, four notable funds houses downgraded Tesla: (1) Citibank, Analyst, Itay Michaeli: On Wed, 27 Mar 2024, analyst lowered price target from $224 to $196. Rating: Neutral. Q1 Delivery: Revised down from 473,300 to 429,9000 EVs. This is a massive, short of 43,400 EVs. Will leave it to the fans to translate that into top line, bottom line and margin. Micha","images":[{"img":"https://community-static.tradeup.com/news/9b35336cfc779802348d66dc13a4d858","width":"1379","height":"468"},{"img":"https://community-static.tradeup.com/news/90fc2631db3946611217348c11f1726f","width":"1046","height":"643"},{"img":"https://community-static.tradeup.com/news/a451a0b1155e54f3ff225fbd062579c0","width":"672","height":"162"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/289834473468104","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157925279,"gmtCreate":1625560884091,"gmtModify":1703743754575,"author":{"id":"4087654114933110","authorId":"4087654114933110","name":"rickson","avatar":"https://community-static.tradeup.com/news/b4ec74585b29736c3976f8e134b58497","crmLevel":1,"crmLevelSwitch":1},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157925279","repostId":"2149033827","repostType":4,"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}